By ANDREW POLLACK
The approval is a huge milestone for MannKind Corporation but concerns linger about the drug’s potential effect on patients’ lungs.
Published: June 28, 2014 at 4:00AM
from NYT Business Day http://ift.tt/1mEDLvI
via IFTTT
from WordPress http://ift.tt/1lWbOPw
No comments:
Post a Comment